News
thumbnail
Deal MakingMerck to buy T-cell engager firm Harpoon for $680mMerck to buy T-cell engager firm Harpoon for $680m
Merck & Co. will acquire Harpoon Therapeutics, adding a pipeline of T-cell engager targeting delta-like ligand 3 (DLL3).
Merck & Co. will acquire Harpoon Therapeutics, adding a pipeline of T-cell engager targeting delta-like ligand 3 (DLL3).